Erythromycin Ethylsuccinate

Gastroparesis, Erythrasma, Whooping Cough + 60 more

Treatment

68 FDA approvals

20 Active Studies for Erythromycin Ethylsuccinate

What is Erythromycin Ethylsuccinate

Erythromycin

The Generic name of this drug

Treatment Summary

Erythromycin is an antibiotic used to treat bacterial infections. It was first discovered in 1952 and belongs to a group of antibiotics called macrolides. Erythromycin can be taken in various forms such as intravenous, topical, and as eye drops. It is effective against both Gram-positive and Gram-negative bacteria.

Erythrocin Stearate

is the brand name

image of different drug pills on a surface

Erythromycin Ethylsuccinate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Erythrocin Stearate

Erythromycin

1964

261

Approved as Treatment by the FDA

Erythromycin, also known as Erythrocin Stearate, is approved by the FDA for 68 uses which include Corynebacterium Infections and Urethritis .

Corynebacterium Infections

Urethritis

Postoperative Infections

urogenital infections during pregnancy

Bacterial Infections

Communicable Diseases

Respiratory Tract Infections

Listeriosis

Communicable Diseases

Whooping Cough

Amebiasis

Common Cold

Rheumatic Fever

Staphylococcal Skin Infections

Urinary Tract Infection (UTI)

Intestinal amebiasis caused by entamoeba histolytica

Corynebacterium minutissimum infection

Pneumonia

Listeria infection

Listeria monocytogenes infection

Erythrasma

Acute Otitis Media caused by Haemophilus Influenzae

Used to treat Acute Otitis Media caused by Haemophilus Influenzae in combination with Sulfisoxazole

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Pneumonia, Mycoplasma

Streptococcus pyogenes

inflammatory papular lesions

Used to treat inflammatory papular lesions in combination with Avobenzone

prophylaxis of Rheumatic fever

treponema pallidum infection

penicillins

Upper Respiratory Tract Infection

Streptococcus Pneumoniae Infections

prophylaxis of Postoperative Infections

Whooping Cough

Bordetella Pertussis Infection

Communicable Diseases

Diphtheria

uncomplicated endocervical infection

Urethritis

Bacterial Infections

Acne Vulgaris

Used to treat predominant skin comedones, papules and pustules in combination with Tretinoin

Primary Syphilis

Corynebacterium Infections

Lower Respiratory Tract Infection (LRTI)

Ureaplasma urethritis

Staphylococcal Skin Infections

Acne Vulgaris

Used to treat Acne Vulgaris in combination with Tretinoin

diphtheria antitoxin

Communicable Diseases

Pertussis

Conjunctivitis

Skin and skin structure infections

Staphylococcus (S.) Aureus Infection

Haemophilus Influenzae Infections

Used to treat Haemophilus Influenzae Infections in combination with null

Urethritis

Legionella pneumophila

Bronchitis

Ureaplasma urealyticum

penicillins

skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes

pustular lesions

Used to treat pustular lesions in combination with Avobenzone

Whooping Cough

Chlamydia Trachomatis

patients with intolerance or contraindications to tetracycline use

Syphilis

First episode of rheumatic fever

Rheumatic Fever

Pneumococcal Infections

Sulfonamides

Effectiveness

How Erythromycin Ethylsuccinate Affects Patients

Erythromycin is an antibiotic that works by preventing bacteria from making proteins, which helps to treat bacterial infections. It can be used to treat many different types of bacteria, but it is important to make sure that the bacteria is susceptible to erythromycin before administering it. It is also important to note that while erythromycin may be used to treat some Haemophilus influenzae, it may be combined with other medications to be effective. Taking erythromycin can also lead to pseudomembranous colitis, which can range from mild to severe, as well as liver issues

How Erythromycin Ethylsuccinate works in the body

Erythromycin is an antibiotic that stops bacteria from reproducing. It does this by binding to the ribosomal proteins that form the building blocks of protein synthesis. This prevents bacteria from making the proteins they need to replicate, leading to bacterial death or an inability to reproduce. Erythromycin has a strong affinity for bacterial ribosomes, making it a broad-spectrum antibiotic.

When to interrupt dosage

The suggested portion of Erythromycin Ethylsuccinate is contingent upon the specified state, such as Chlamydia Trachomatis, penicillins and Syphilis. The measure of dosage is contingent upon the method of delivery (e.g. Granule, for suspension or Tablet, film coated - Oral) specified in the table below.

Condition

Dosage

Administration

Postoperative Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Listeria monocytogenes infection

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

prophylaxis of Postoperative Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Corynebacterium Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

treponema pallidum infection

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

First episode of rheumatic fever

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Erythrasma

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Chancroid

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Syphilis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Urethritis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Listeriosis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Endophthalmitis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

penicillins

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Bacterial Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Conjunctivitis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Amebiasis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Rheumatic Fever

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid, Liquid - Oral, Capsule, Capsule - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Kit - Topical, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Powder, for suspension - Oral, Swab, Swab - Topical, Tablet, coated - Oral, Tablet, coated, Powder - Oral, Powder, for solution - Oral, Lotion; Swab, For suspension, For suspension - Oral

Warnings

Erythromycin Ethylsuccinate has nine counterindications and should be avoided when facing the conditions detailed in the subsequent table.

Erythromycin Ethylsuccinate Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Erythromycin may interact with Pulse Frequency

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Erythromycin Ethylsuccinate.

Common Erythromycin Ethylsuccinate Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Erythromycin.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Erythromycin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Erythromycin.

Erythromycin Ethylsuccinate Toxicity & Overdose Risk

The lowest toxic dose of erythromycin in rats has been found to be 9272mg/kg. Symptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting, and should be treated by immediately discontinuing the drug and attempting to rapidly remove any unabsorbed drug. Dialysis will not help remove the drug from the body.

image of a doctor in a lab doing drug, clinical research

Erythromycin Ethylsuccinate Novel Uses: Which Conditions Have a Clinical Trial Featuring Erythromycin Ethylsuccinate?

Currently, 53 active trials are evaluating the potential of Erythromycin Ethylsuccinate to provide relief from Streptococcus pyogenes, Treponema pallidum infection and Rheumatic Fever.

Condition

Clinical Trials

Trial Phases

Listeriosis

0 Actively Recruiting

Legionella pneumophila

0 Actively Recruiting

Acne Vulgaris

13 Actively Recruiting

Phase 4, Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3

Gastroparesis

13 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1

Acne Vulgaris

0 Actively Recruiting

treponema pallidum infection

0 Actively Recruiting

Corynebacterium minutissimum infection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Urinary Tract Infection (UTI)

5 Actively Recruiting

Phase 1, Phase 3, Phase 4, Not Applicable

Ureaplasma urealyticum

0 Actively Recruiting

Acne Vulgaris

5 Actively Recruiting

Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Pneumococcal Infections

0 Actively Recruiting

Common Cold

3 Actively Recruiting

Not Applicable

Acne Vulgaris

0 Actively Recruiting

Urethritis

1 Actively Recruiting

Phase 2

penicillins

1 Actively Recruiting

Phase 3

Chlamydia Trachomatis

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Primary Syphilis

0 Actively Recruiting

Respiratory Tract Infections

2 Actively Recruiting

Phase 3, Not Applicable

Erythromycin Ethylsuccinate Reviews: What are patients saying about Erythromycin Ethylsuccinate?

5

Patient Review

11/28/2008

Erythromycin Ethylsuccinate for Throat Infection caused by Streptococcus Pneumoniae

I had a really bad sore throat and wasn't sure what was wrong. The doctor I saw couldn't give me a definite answer, but the liquid medication they prescribed started working within 48 hours.

5

Patient Review

5/31/2017

Erythromycin Ethylsuccinate for Skin Infection

Ever since I started taking these tablets, I've noticed an unpleasant smell coming from my body. I'm not sure if it's the pills or just a coincidence.

3.3

Patient Review

3/8/2019

Erythromycin Ethylsuccinate for Acute Bacterial Infection of the Sinuses

This medication caused me to experience hearing loss.

2.7

Patient Review

10/4/2015

Erythromycin Ethylsuccinate for Pneumonia caused by Bacteria

While this antibiotic did cure my illness, the side effects were very difficult to handle. I experienced stomach issues, diarrhea, nausea, and chest pain; however, I was willing to endure all of it for the greater good.

2.3

Patient Review

7/26/2008

Erythromycin Ethylsuccinate for Acne

For the past four days, I've constantly felt nauseous and had diarrhea for three of those days. It's been tough on my stomach!

1.3

Patient Review

9/7/2015

Erythromycin Ethylsuccinate for Acute Bacterial Infection of the Sinuses

I was prescribed this by my doctor for severe flu/cough symptoms, but I stopped taking it after a few days because the stomach pains and nausea were so bad. I felt worse than before, and my blood pressure dropped to 88/54. Not happy!

1

Patient Review

12/27/2019

Erythromycin Ethylsuccinate for Acute Streptococcus Pyogenes Bacteria Infection of Sinuses

I would not recommend this medication to anyone. I was given it for a sore throat, but after taking it my chest pain increased and I developed a painful cough that I didn't have before. My doctor also prescribed this to my son and he is having the same issues.

1

Patient Review

1/18/2008

Erythromycin Ethylsuccinate for Strep Throat

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about erythromycin ethylsuccinate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is erythromycin the same as erythromycin ethylsuccinate?

"Erythromycin ethylsuccinate is an ester of erythromycin which is suitable for oral administration. It is chemically known as erythromycin 2'-(ethylsuccinate). The base, the stearate salt, and the esters of erythromycin are poorly soluble in water."

Answered by AI

How long is erythromycin ethylsuccinate good for?

"The recommended dosage of erythromycin ethylsuccinate for streptococcal infections is at least 10 days."

Answered by AI

What bacteria is erythromycin used to treat?

"This medication is effective against bacteria that cause infections of the skin and upper respiratory tract, including Streptococcus, Staphylococcus, Haemophilus, and Corynebacterium genera."

Answered by AI

What is erythromycin ethylsuccinate used for?

"Erythromycin ethylsuccinate is a medication used to treat various infections caused by bacteria. It can be used alone or with other drugs. Erythromycin ethylsuccinate belongs to a class of drugs known as macrolides."

Answered by AI

Clinical Trials for Erythromycin Ethylsuccinate

Image of Seattle Children's Hospital in Seattle, United States.

Follow-Up Strategies for Children With Medical Complexity

1 - 16
All Sexes
Seattle, WA

Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection. Families will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.

Waitlist Available
Has No Placebo

Seattle Children's Hospital

Nassr Nama, MD, MSc

Image of Biomedical Engineering Building in Austin, United States.

Focused Ultrasound Stimulation for Gastroparesis

18 - 70
All Sexes
Austin, TX

This randomized, sham-controlled crossover pilot study will evaluate whether noninvasive gastric focused ultrasound stimulation is associated with changes in postprandial gastric electrical activity and gastrointestinal symptoms in adults with gastroparesis or delayed gastric emptying. Participants will complete one active FUS visit and one sham-stimulation visit in randomized order, separated by at least 48 hours. At each visit, electrogastrography will be recorded before and after a standardized liquid nutritional drink, during active or sham stimulation, and during recovery. Gastrointestinal symptoms will be assessed at prespecified time points using the Total Symptom Score questionnaire.

Recruiting
New This Month

Biomedical Engineering Building

Huiliang Wang, PhD

Have you considered Erythromycin Ethylsuccinate clinical trials?

We made a collection of clinical trials featuring Erythromycin Ethylsuccinate, we think they might fit your search criteria.
Go to Trials
Image of University of Louisville Clinical Trials Unit in Louisville, United States.

Gastric Electrical Stimulation for Gastroparesis

18+
All Sexes
Louisville, KY

Gastroparesis is a disorder characterized by delayed gastric emptying and symptoms including nausea, vomiting, and abdominal pain. Gastric electrical stimulation (GES) using the implanted Enterra™ neurostimulator is FDA-approved to treat nausea and vomiting but its impact on abdominal pain has not been well studied. This study evaluates whether alternative programming parameters of the Enterra™ device can reduce abdominal pain in patients with gastroparesis. Participants with an existing Enterra™ device will be randomized to one of three stimulation settings and followed for assessment of pain, gastrointestinal symptoms, quality of life, and medication use.

Waitlist Available
Has No Placebo

University of Louisville Clinical Trials Unit

Have you considered Erythromycin Ethylsuccinate clinical trials?

We made a collection of clinical trials featuring Erythromycin Ethylsuccinate, we think they might fit your search criteria.
Go to Trials
Image of Direct Helpers in Hialeah, United States.

Rifaximin + ORT for Diarrhea

6 - 12
All Sexes
Hialeah, FL

The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are: How does rifaximin 200 mg move through and leave the body in children with acute diarrhea? Is rifaximin safe for children in this age group? Does rifaximin plus ORT help resolve diarrhea faster than ORT alone? Researchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes. Participants will: Take one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone Receive oral rehydration therapy according to the investigator's standard of care Attend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls Provide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only) Provide stool samples to identify bacterial pathogens Keep a diary of stool frequency and consistency to help determine when diarrhea resolves Be monitored for side effects, vital signs, and laboratory changes

Phase 4
Recruiting

Direct Helpers (+9 Sites)

Bausch Health Americas, Inc.

Have you considered Erythromycin Ethylsuccinate clinical trials?

We made a collection of clinical trials featuring Erythromycin Ethylsuccinate, we think they might fit your search criteria.
Go to Trials